Ocumension Therapeutics’ NDA accepted by China’s NMPA
Ocumension Therapeutics said the NMPA accepted its NDA for OT-301, also described as NCX 470 with bimatoprost genod.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.